SAVR (balloon-expandable: risk adjusted OR = 0.50, p = 0.031 self-expanding: OR = 0.20, p 48 h were significantly in favor of TAVR. After risk adjustment, balloon-expandable as well as self-expanding transfemoral TAVR were associated with a significantly lower mortality vs. SAVR (5.71%), transfemoral TAVR showed better outcomes, with self-expanding compared to balloon-expandable transfemoral TAVR having significantly lower in-hospital mortality (2.41% vs. While results indicate a slightly higher unadjusted in-hospital mortality for transapical TAVR (6.00%) vs. Patients treated with TAVR were older, showed a higher logistic EuroSCORE, and had more pre-existing diseases. Results: 4,861 procedures-4,025 SAVR and 836 TAVR-for aortic regurgitation were identified. Methods: By use of health records, we analyzed all isolated TAVR or surgical aortic valve replacements (SAVR) for pure aortic regurgitation between 20 in Germany. Due to constant development of TAVR, it is necessary to analyze current data. 3Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germanyīackground: In pure aortic regurgitation, transcatheter aortic valve replacement (TAVR) is not yet used on a regular base.2Center for Big Data Analysis in Cardiology (CeBAC), Department of Cardiology and Angiology, University Heart Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

1Department of Cardiology and Angiology, University Heart Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.Vera Oettinger 1,2* ‡, Ingo Hilgendorf 1,‡, Dennis Wolf 1,‡, Peter Stachon 1,2,‡, Adrian Heidenreich 1,2, Manfred Zehender 1,2, Dirk Westermann 1,‡, Klaus Kaier 2,3,†,‡ and Constantin von zur Mühlen 1,2,†,‡

Heart pro total heart health